Diabetic neuropathy is one of the most common and frustrating complications of diabetes. It can produce burning, stabbing, electric-shock sensations, tingling, extreme sensitivity and numbness—often beginning in the toes and feet and gradually moving upward. For some people, the pain becomes severe enough to interfere with sleep, walking, work and everyday activities. Standard medications such as pregabalin, gabapentin, duloxetine and certain antidepressants can help, but none works for everyone. That treatment gap has led increasing numbers of patients to ask whether medical marijuana can relieve painful diabetic neuropathy.
Clinical evidence suggests that the answer may be yes for some patients, particularly with THC-containing cannabis products, but the benefit needs to be kept in perspective. Several randomized trials have found reductions in diabetic nerve pain, including a University of California, San Diego study directly testing inhaled cannabis and a more recent 100-patient placebo-controlled trial of a transdermal THC:CBD formulation. At the same time, major diabetes guidelines still recommend established neuropathic-pain medications before cannabis, and the FDA has not approved botanical marijuana for diabetic neuropathy or any other pain disorder. Medical cannabis is therefore best considered a possible symptom-management option for selected patients, not a treatment proven to repair diabetic nerve damage.
What Is Diabetic Neuropathy?
Diabetic peripheral neuropathy develops when prolonged metabolic abnormalities associated with diabetes damage peripheral nerves and the small blood vessels that supply them. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that up to half of people with diabetes develop peripheral neuropathy. Symptoms typically begin in the feet and may include burning, pins and needles, numbness, weakness, shooting pain or severe sensitivity to even light touch. Symptoms often become more noticeable at night, which helps explain why painful diabetic neuropathy can have such a large effect on sleep and quality of life.
Pain is only part of the problem. Diabetic neuropathy can also reduce the ability to feel heat, pressure and injuries. Someone may experience severe burning in one area of the foot while failing to notice a blister or cut somewhere else. The CDC warns that nerve damage and reduced circulation can allow small injuries to develop into ulcers and infections, sometimes ultimately leading to amputation. This distinction becomes extremely important when discussing marijuana: reducing neuropathic pain does not mean the underlying neuropathy has disappeared or that the feet are protected from injury.
The UC San Diego Trial of Cannabis for Diabetic Nerve Pain
One of the most important direct studies was conducted by researchers at the University of California, San Diego School of Medicine. The randomized, double-blind, placebo-controlled crossover trial enrolled 16 people with painful diabetic peripheral neuropathy. During separate laboratory sessions, participants received placebo cannabis or cannabis containing approximately 1%, 4% or 7% THC. Researchers repeatedly measured spontaneous nerve pain, experimentally triggered pain and cognitive performance during the hours following administration.
The results showed a statistically significant dose-dependent reduction in spontaneous pain, with the 7% THC cannabis producing the greatest analgesic effect. The higher dose also reduced certain forms of pain triggered by light stimulation. However, increased THC came with a cost: participants receiving the highest dose performed worse on two of three neuropsychological tests. The trial therefore demonstrated both sides of the medical-cannabis equation. THC can measurably reduce painful diabetic neuropathy, but escalating the dose can also increase cognitive impairment. Because the study included only 16 people and examined effects over several hours rather than months or years, it does not establish the long-term effectiveness or safety of regularly smoking or inhaling cannabis for diabetic neuropathy.
A Newer Trial of Transdermal THC, CBD and CBN
A considerably larger randomized study published in late 2024 examined a different approach: transdermal cannabinoids applied to the lower extremities. Researchers affiliated with Khon Kaen University and Thailand’s Ministry of Public Health enrolled 100 participants with painful diabetic peripheral neuropathy in a double-blind, placebo-controlled trial lasting 12 weeks. Participants received either a standardized transdermal formulation containing THC, CBD and cannabinol (CBN) or a matching placebo. Pain was measured using the Neuropathic Pain Symptom Inventory.
The results were striking. Average total neuropathic-pain scores in the cannabinoid group declined from about 25.6 at baseline to 5.57 by the end of treatment, compared with a much smaller reduction—from 25.24 to 22.85—in the placebo group. Improvements were reported at weeks four, eight and twelve, and adverse events were generally mild. The study is important because it directly targeted painful diabetic neuropathy of the lower extremities rather than lumping diabetic neuropathy together with many unrelated chronic-pain conditions. Nevertheless, it remains one trial of one proprietary cannabinoid formulation. Replication by independent research groups and longer follow-up will be necessary before transdermal THC:CBD can be considered an established diabetic-neuropathy treatment.
What Larger Cannabis Reviews Say
The U.S. Agency for Healthcare Research and Quality provides useful perspective through its 2025 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain. The final update included 29 randomized controlled trials and found that people with chronic pain—predominantly neuropathic pain—may experience small short-term reductions in pain from certain cannabis products. Products containing a relatively high proportion of THC and products containing comparable amounts of THC and CBD showed the clearest evidence of benefit.
The improvements were generally modest. Comparable THC/CBD formulations produced small improvements in pain severity and overall function, while high-THC preparations also reduced pain in some trials. CBD-dominant products and CBD alone generally did not demonstrate consistent improvement in pain or function. THC-containing products also increased adverse effects, particularly dizziness, sedation and nausea. The review specifically incorporated the newer transdermal diabetic-neuropathy trial, which broadens the evidence base but does not change the fundamental conclusion: cannabinoids appear capable of reducing neuropathic pain in some patients, but the average benefit is limited and long-term outcomes remain inadequately studied.
Is THC or CBD Better for Diabetic Neuropathy?
The available evidence currently favors THC-containing treatment over CBD alone for direct neuropathic-pain relief. THC activates cannabinoid receptors involved in pain signaling and has produced measurable analgesia in controlled neuropathy studies. Balanced THC/CBD formulations also have supportive chronic-pain evidence. CBD is appealing because it does not produce the characteristic THC high, but current randomized evidence does not demonstrate that CBD by itself reliably relieves diabetic neuropathic pain. AHRQ’s review found little evidence of meaningful pain or functional improvement from low-THC/high-CBD formulations.
That does not mean the strongest THC product is the best choice. The UC San Diego study demonstrated increasing pain relief with increasing THC exposure, but cognitive impairment also became more prominent. People with diabetic neuropathy may already have balance problems because nerve damage can interfere with sensation and proprioception. Adding THC-related dizziness or impaired coordination can therefore create a significant fall risk, particularly in older adults. The practical goal is not maximum THC exposure—it is the lowest cannabinoid exposure that provides worthwhile symptom relief without unacceptable intoxication, sedation or instability.
Where Cannabis Fits Compared With Standard Treatments
Medical cannabis is not currently listed as a first-line treatment for painful diabetic neuropathy in major U.S. diabetes guidelines. The American Diabetes Association‘s 2026 Standards of Care recommend gabapentinoids such as pregabalin or gabapentin, serotonin-norepinephrine reuptake inhibitors such as duloxetine, tricyclic antidepressants and sodium-channel blockers as initial pharmacological treatment classes. ADA also supports combination therapy when a single medication does not provide adequate relief and advises against routine opioid treatment because of its risks.
The American Academy of Neurology reaches a similar conclusion. Its evidence-based guideline recommends that clinicians offer TCAs, SNRIs, gabapentinoids or sodium-channel blockers for painful diabetic polyneuropathy and consider switching to a different effective class when the first medication fails or causes unacceptable side effects. Cannabis is not included among the guideline’s established first-line drug classes. This does not mean cannabinoids have no potential role; rather, the evidence supporting conventional neuropathic-pain medications remains broader and more mature. Medical cannabis is most reasonably considered when standard therapies provide inadequate relief, create intolerable adverse effects, or when a clinician and patient decide that a carefully monitored cannabinoid trial is appropriate.
Cannabis Does Not Reverse Diabetic Nerve Damage
One of the most important misconceptions surrounding cannabis and neuropathy is that reducing pain means the nerves are healing. The ADA’s 2026 Standards explicitly state that there is currently no specific treatment that reverses established diabetic nerve damage. Optimizing glucose management can prevent or delay neuropathy in type 1 diabetes and may slow progression in type 2 diabetes, while controlling weight, blood pressure and cholesterol can further reduce risk. Pain medications—including cannabinoids when they work—primarily change how symptoms are experienced.
This distinction matters especially when cannabis provides noticeable relief. A person may feel less burning or stabbing pain while still having substantial loss of protective sensation. The CDC recommends that people with diabetes check their feet every day because cuts, blisters and ulcers may develop without being felt. Anyone using medical cannabis for neuropathic foot pain should continue routine foot examinations and should not use symptom relief as evidence that a wound, infection or circulation problem has resolved. New redness, swelling, drainage, ulcers, warmth or nonhealing injuries require medical evaluation regardless of how well cannabis controls the pain.
Special Risks for People With Diabetes
Cannabis use introduces several concerns that are particularly relevant to diabetes. Dizziness and sedation can compound the balance problems already associated with peripheral neuropathy. Cannabis intoxication may also interfere with medication schedules, glucose monitoring, meal planning or recognition of hypoglycemia in susceptible patients. The ADA’s 2026 Standards additionally discuss cannabis use in people with diabetes and note reports linking cannabis use in type 1 diabetes with hyperglycemic ketosis and cannabinoid hyperemesis syndrome, a condition involving recurrent severe nausea and vomiting among some frequent cannabis users.
Drug interactions require attention as well. Many people with diabetic neuropathy take several medications simultaneously, potentially including gabapentin, pregabalin, duloxetine, antihypertensive drugs, anticoagulants and glucose-lowering medications. CBD can alter the metabolism of certain medications, and FDA specifically warns that cannabidiol can cause liver injury, sedation and clinically important drug interactions. Botanical marijuana and most retail CBD products have not been FDA approved to treat diabetic neuropathy, meaning standardized effectiveness, dosing, drug-interaction data and manufacturing quality cannot be assumed from product to product.
Smoking, Edibles and Topicals Are Different Treatments
The way cannabis is taken changes both its effects and its risks. Inhaled cannabis acts rapidly, which may allow users to recognize the effect of a dose relatively quickly, but smoking exposes the lungs and cardiovascular system to combustion products. Edibles avoid smoke but have delayed and often longer-lasting effects, increasing the possibility of taking additional THC before the first dose has fully taken effect. High-dose edibles can therefore produce prolonged intoxication, dizziness or anxiety that may be particularly problematic for someone already unsteady from neuropathy.
Topical and transdermal formulations are especially interesting in diabetic neuropathy because treatment can theoretically be directed toward painful feet and lower legs while minimizing systemic intoxication. The recent THC:CBD transdermal trial offers encouraging evidence for this strategy. It would nevertheless be premature to assume that every dispensary CBD cream or cannabis balm will produce the same results. The FDA warns that nonapproved cannabis products have not been evaluated for standardized dosing, effectiveness, interactions or product quality, and commercially marketed cannabinoid concentrations may not reliably reproduce the formulation used in a clinical trial.
The Bottom Line
Medical marijuana may reduce painful diabetic neuropathy in some patients, and the evidence is stronger than it was only a few years ago. A small UC San Diego randomized trial demonstrated dose-dependent pain relief from inhaled THC, although higher THC exposure also impaired cognitive performance. More recently, a 100-person randomized placebo-controlled trial found substantial improvement with a transdermal THC:CBD formulation applied for 12 weeks. Broader AHRQ reviews also conclude that THC-containing and balanced THC/CBD cannabis products can provide small short-term improvements in predominantly neuropathic pain populations.
The evidence does not show that marijuana repairs damaged nerves, prevents diabetic foot ulcers or replaces management of blood glucose, blood pressure, cholesterol and other diabetes risks. Current ADA and AAN guidelines continue to favor pregabalin, gabapentin, duloxetine, tricyclic antidepressants and related drug classes as established initial treatments. For patients whose pain remains inadequately controlled, medical cannabis may be worth discussing as an additional option, particularly where regulated products and medical supervision are available. The best treatment is one that reduces burning and shooting pain while preserving alertness, balance, mobility and the ability to recognize and protect an injured diabetic foot.
